When was InteGen founded?

InteGen was founded in 2011 and raised its 1st funding round within a year of its incorporation.

Where is InteGen located?

InteGen is headquartered in Orlando, United States.

Who is the current CEO of InteGen?

Ramesh Babu Chakliath of InteGen. They have also founded 1 company and are angel investors in 4 startups, including .

How many employees does InteGen have?

As of Aug 31, 2026, the latest employee count at InteGen is 5.

Is InteGen a funded company?

InteGen is a funded company, having raised a total of $4.64M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 24, 2011.

When was the latest funding round of InteGen?

InteGen's latest funding was a $***** Series A round on Oct 23, 2018, with participation from 0 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $1.23B in funding in 2026 to date.

Where does InteGen rank among its competitors?

InteGen ranks 62nd amongst 182 active competitors, of which 28 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was BioLamina, which secured $23.6M in Apr, 2026.

Who are the top competitors of InteGen?

InteGen's top competitors include BioLife Solutions, Integrated DNA Technologies and RoosterBio. Among them, BioLamina secured the most recent funding round in April, 2026.

InteGen - 2026 Company Profile, Team, Funding & Competitors

Company Details

InteGen LLC is a biotechnology company dedicated to providing reagents/tools for the cytogenetics community. It specifically develops and markets DNA FISH probes that can be used in the individual chromosome profiling in interphase cells for hematologic malignancies and genetic disorders including miscarriages. Additionally, the company also markets other products for cytogenetic studies.

Website: integenllc.com
Phone Number: +1 **********

Key Metrics

Founded Year

2011

Location

Orlando, United States

Stage

Series A

Total Funding

$4.64M in 2 rounds

Latest Funding Round

Series A, Oct 23, 2018, $*****

Investors

VentureHealth

Ranked

62^nd among 182 active competitors

Employee Count

5 as on Aug 31, 2026

Similar Companies

BioLife Solutions & 197 more

View InteGen's full profile

InteGen has raised a total funding of $4.64M over 2 rounds. Its first funding round was on Jan 24, 2011. InteGen has 1 institutional investor.

Here is the list of recent funding rounds of InteGen:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 23, 2018	9261227	Series A	2479041	7928264	2842417	5319388
Jan 24, 2011	3565216	Seed	2210165	6077065	8195867	9353696

Access funding benchmarks and valuations. Sign up today!

View details of InteGen's funding rounds and investors

The founders of InteGen is Ramesh Babu Chakliath. Ramesh Babu Chakliath is the CEO of InteGen.

Here are the details of InteGen's key team members:

Ramesh Babu Chakliath: Founder & CEO of InteGen. They are also an angel investor in 4 startups.
Contact Info: 1 email address and 1 phone number

View details of InteGen's Founder profiles and Board Members

InteGen's employee count trend

InteGen has 5 employees as of Aug 26. Here is InteGen's employee count trend over the years:

Uncover InteGen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of InteGen include BioLife Solutions, Integrated DNA Technologies and RoosterBio. Here is the list of Top 10 competitors of InteGen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BioLife Solutions 1987, Bothell (United States), Acquired	Developer of cell and gene therapies with the integrity of a single cell	-	-	67/100
2nd	Integrated DNA Technologies 1987, Coralville (United States), Acquired	Provider of oligonucleotide-based reagents and kits	-	Summit Partners, Golub Capital & 1 others	63/100
3rd	RoosterBio 2012, Frederick (United States), Series B	Developer of human mesenchymal stem cells and extracellular vesicles	$38.4M	Planetary Technologies, Dynamk Capital & 4 others	57/100
4th	BioLamina 2008, Sundbyberg (Sweden), Series B	Cell culture reagents for stem cell research	$18.2M	Lauxera Capital Partners, Bure Equity & 5 others	56/100
5th	Shanghai Doning Biotechnology 2005, Shanghai (China), Series C	Provider of cell culture media	$14.9M	HongShan, Ally Bridge Group & 1 others	53/100
6th	ArcticZymes 2009, Tromso (Norway), Public	Developer of recombinant enzymes from various arctic species	-	Northislet, Europa	49/100
7th	Toyobo 1882, New York City (United States), Public	Manufacturer of high performance materials including films and functional textiles	-	-	49/100
8th	Multus 2019, London (United Kingdom), Series A	Provider of lab-grown meat alternatives	$9.3M	SOSV, Big Idea Ventures & 26 others	45/100
9th	Xcell Therapeutics 2015, Seoul (South Korea), Public	Provider of serum-free media for cell culture	-	Positive Investment, Ncore Ventures & 3 others	45/100
10th	Biotangents 2015, Edinburgh (United Kingdom), Series A	Developer of diagnostic assays for infectious diseases in veterinary medicine	$5.62M	Kelvin Capital, Scottish Enterprise & 44 others	45/100
62nd	InteGen 2011, Orlando (United States), Series A	Provider of cytogenetics, DNA FISH probes for research application	$4.64M	VentureHealth	30/100